ReviewNPJ Parkinson's disease2025
Speech and language biomarkers for Parkinson's disease prediction, early diagnosis and progression.
Review in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Associations Between Digital Exclusion and Physical or Cognitive Function in Middle-Aged and Older Adults: Systematic Review and Meta-Analysis.JMIR aging · 2026Pooled it
- Diagnostic performance of PET-based artificial intelligence for differentiating Parkinson's disease from normal controls or atypical parkinsonism: a systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- A Pilot Study of VGGish-CNN as a Model for the Classification of Parkinson's Disease from a Control Group Using Speech Impairment, Integrated with Explainable Artificial Intelligence.Bioengineering (Basel, Switzerland) · 2026Article
- Toward Interpretable Voice-Based Parkinson's Disease Screening via Joint Transfer Function-Feature-Classifier-Ensemble Selection.Bioengineering (Basel, Switzerland) · 2026Article
- Wearable device for tremor-like motion acquisition: a low-cost device using 3D printing for research and education.HardwareX · 2026Article
- Breathe, Eat, Talk: Three Essential Ingredients to Quality-of-Life Outcomes in Movement Disorders.Movement disorders clinical practice · 2026Review
- Demographic Confounding in Voice-Based Parkinson Disease Screening: Methodological Analysis of the Bridge2AI Voice Dataset.Journal of medical Internet research · 2026Article
- Large language model analysis of real-world phone calls reveals prodromal and progressive biomarker of parkinsonism: A two-year proof-of-concept study.PLOS digital health · 2026Article
- A Machine Learning Approach to Voice-Based Parkinson Disease Screening Using Multiview Spectrogram and Speech Recognition Features: Diagnostic Study.JMIR medical informatics · 2026Article
- Use of machine learning and voice for multiclass classification of Parkinson's disease, chronic obstructive pulmonary disease, and healthy controls.Scientific reports · 2026Article
- Metabolic stress exacerbates Parkinson's disease pathology through mitochondrial dysfunction and ferroptosis.NPJ Parkinson's disease · 2026Article
- Machine Learning Approaches to Early Detection of Parkinson's Disease Using Speech Analysis Technique.Neurology international · 2026Article
- Artificial intelligence revolutionizing CNS drug discovery and development.Drug discovery today · 2026Review
- eXCube2: Explainable Brain-Inspired Spiking Neural Network Framework for Emotion Recognition from Audio, Visual and Multimodal Audio-Visual Data.Biomimetics (Basel, Switzerland) · 2026Article
- Development and validation of the dysarthria impact scale: a patient-reported outcome for motor speech disorders.Journal of neurology · 2026Article
- Insights from a cross-sectional population-based study of 10,929 Australians living with Parkinson's disease: risk factors, comorbidities, and sex differences.The Lancet regional health. Western Pacific · 2026Article
- Acupuncture for Early Parkinson's Motor Symptoms: A Multicenter Randomized Controlled Trial Protocol.Neuropsychiatric disease and treatment · 2026Article
- MIL-O-PD: a two-stage multiple instance learning and heuristic optimization framework for unpaired multimodal Parkinson's diagnosis.Frontiers in aging neuroscience · 2026Article
- Factors associated with self- perceived speech impairment inFrontiers in aging neuroscience · 2026Article
- Speech and language outcome measures in clinical trials of Alzheimer's and Parkinson's diseases.Expert review of neurotherapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD), a multifaceted neurodegenerative disorder, can manifest as an array of motor and non-motor symptoms. Among these, speech and language impairments are particularly prevalent, often preceding motor dysfunctions. Emerging research indicates that these impairments may serve as early disease indicators. In this narrative review, we synthesised current findings on the potential of speech and language symptoms in PD identification and progression monitoring. Our review highlights convergent, albeit preliminary, lines of evidence supporting the value of speech-related features in detecting early or prodromal PD, even across language groups, especially with sophisticated analytical techniques. Distinct speech patterns in PD subtypes and other neurological disorders may assist in differential diagnosis and inform targeted management efforts. These features also evolve over the disease course and could effectively be utilised for disease tracking and guide management plan modifications. Advances in digital voice processing allow cost-effective, remote and scalable monitoring for larger populations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.